Tilray’s German subsidiary CC Pharma receives innovation award. The company is also recording record sales and driving expansion in the US beverage market.
The cannabis and consumer goods group Tilray Brands can report success in Germany. The German subsidiary CC Pharma was recognized as a “TOP 100 Innovator” in Germany on February 4, 2026. The award recognizes innovation management and future-oriented strategies in medium-sized companies.
CC Pharma is a central component of Tilray’s European strategy. The company supplies over 13,000 pharmacies in Germany with prescription and over-the-counter medications. The subsidiary also plays an important role in the distribution of medical cannabis in the regulated German healthcare system.
Expansion in the US beverage market
In parallel to its European pharmaceutical business, Tilray is pursuing a diversification strategy in the US alcohol market. A new distribution partnership with Romano Beverage was recently agreed for the subsidiary Breckenridge Distillery in order to expand the reach of the spirits products in Illinois.
Should investors sell immediately? Or is it worth joining? Tilray?
On February 3, Tilray announced events and specials at its craft beer taprooms nationwide – including brands like SweetWater Brewing, Montauk Brewing Company and Blue Point Brewing Co. The promotions targeted a major sporting event.
Financial development
On January 8, the company reported record sales for the second quarter of fiscal 2026. The growth drivers were the international medical cannabis segment and the distribution business.
The cannabis industry faces several milestones in 2026. Observers are turning their attention to possible federal reforms in the US, changing consumer habits and the importance of strong brand identities in an increasingly saturated market. Regulatory shifts and banking reforms remain key issues for long-term industry development.
Key facts:
- CC Pharma named “TOP 100 Innovator” (February 4, 2026)
- Sales network includes over 13,000 pharmacies in Germany
- New distribution partnership for Breckenridge Distillery in Illinois
- Record sales in the second quarter of the 2026 financial year
- Active brand promotion of the US craft beer sector
Tilray Stock: Buy or Sell?! New Tilray analysis from February 10 provides the answer:
The latest Tilray figures speak for themselves: there is an urgent need for action for Tilray shareholders. Is it worth getting started or should you sell? In the current free analysis from February 10th you will find out what to do now.
Tilray: Buy or Sell? Read more here…
date: 2026-02-10 01:52:00
Related reading